Revelation Biosciences

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering immunology-based therapies and diagnostic tools aimed at preventing and treating a range of illnesses. Their flagship therapeutic, REVTx-99, is an intranasal immunomodulator designed to both prevent and treat a broad spectrum of respiratory viral infections, including SARS-CoV-2 (and its variants), influenza A and B, parainfluenza, rhinovirus, and RSV. Furthermore, its potential extends to addressing allergic rhinitis and chronic nasal congestion. The company's pipeline also includes REVTx-200, an intranasal immunomodulator intended as an adjunct to enhance the efficacy of intramuscular vaccinations, thereby boosting immunity. Additionally, they are developing REVDx-501, a rapid diagnostic test designed for convenient home use to detect respiratory viral infections. Established in 2019, the company is headquartered in New York, New York.